NASDAQ:BFRA - BIOFRONTERA AG/ADR Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BIOFRONTERA AG/ADR Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.25 -0.10 (-0.88 %) (As of 01/26/2020 04:00 PM ET) Add Compare Today's Range$11.25Now: $11.25▼$11.4050-Day Range$9.90MA: $10.55▼$12.1052-Week Range$9.00Now: $11.25▼$18.32Volume362 shsAverage Volume162 shsMarket Capitalization$252.23 millionP/E RatioN/ADividend YieldN/ABeta0.74 ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BFRA Previous Symbol CUSIPN/A CIKN/A Webhttp://www.biofrontera.com/ Phone011-49-2148-7600Debt Debt-to-Equity Ratio1.56 Current Ratio1.99 Quick Ratio1.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$24.93 million Price / Sales10.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book12.93Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-10,480,000.00 Net Margins-23.35% Return on Equity-34.45% Return on Assets-10.01%Miscellaneous Employees149 Outstanding Shares22,420,000Market Cap$252.23 million Next Earnings Date5/4/2020 (Estimated) OptionableNot Optionable Receive BFRA News and Ratings via Email Sign-up to receive the latest news and ratings for BFRA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BFRA Rates by TradingView BIOFRONTERA AG/ADR (NASDAQ:BFRA) Frequently Asked Questions What is BIOFRONTERA AG/ADR's stock symbol? BIOFRONTERA AG/ADR trades on the NASDAQ under the ticker symbol "BFRA." How were BIOFRONTERA AG/ADR's earnings last quarter? BIOFRONTERA AG/ADR (NASDAQ:BFRA) posted its quarterly earnings results on Tuesday, November, 19th. The company reported ($0.59) earnings per share (EPS) for the quarter. The firm had revenue of $5.85 million for the quarter. BIOFRONTERA AG/ADR had a negative net margin of 23.35% and a negative return on equity of 34.45%. View BIOFRONTERA AG/ADR's Earnings History. When is BIOFRONTERA AG/ADR's next earnings date? BIOFRONTERA AG/ADR is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for BIOFRONTERA AG/ADR. What guidance has BIOFRONTERA AG/ADR issued on next quarter's earnings? BIOFRONTERA AG/ADR updated its fourth quarter 2019 Pre-Market earnings guidance on Friday, January, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $13.542-13.542 million, compared to the consensus revenue estimate of $11.45 million. What price target have analysts set for BFRA? 2 brokerages have issued 12-month price objectives for BIOFRONTERA AG/ADR's stock. Their forecasts range from $11.00 to $18.00. On average, they anticipate BIOFRONTERA AG/ADR's share price to reach $14.50 in the next year. This suggests a possible upside of 28.9% from the stock's current price. View Analyst Price Targets for BIOFRONTERA AG/ADR. What is the consensus analysts' recommendation for BIOFRONTERA AG/ADR? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOFRONTERA AG/ADR in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOFRONTERA AG/ADR. Has BIOFRONTERA AG/ADR been receiving favorable news coverage? News coverage about BFRA stock has trended extremely negative on Sunday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. BIOFRONTERA AG/ADR earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for BIOFRONTERA AG/ADR. Who are some of BIOFRONTERA AG/ADR's key competitors? Some companies that are related to BIOFRONTERA AG/ADR include Revance Therapeutics (RVNC), Akebia Therapeutics (AKBA), Amphastar Pharmaceuticals (AMPH), XBiotech (XBIT), Odonate Therapeutics (ODT), RAPT Therapeutics (RAPT), Phathom Pharmaceuticals (PHAT), Applied Therapeutics (APLT), Gossamer Bio (GOSS), Radius Health (RDUS), Achillion Pharmaceuticals (ACHN), G1 Therapeutics (GTHX), Stoke Therapeutics (STOK), Endonovo Therapeutics (ENDV) and Kiniksa Pharmaceuticals (KNSA). What other stocks do shareholders of BIOFRONTERA AG/ADR own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIOFRONTERA AG/ADR investors own include GW Pharmaceuticals PLC- (GWPH), Gilead Sciences (GILD), Pattern Energy Group (PEGI), Supernus Pharmaceuticals (SUPN), AbbVie (ABBV), Bank of Nova Scotia (BNS), Energy Transfer LP Unit (ET), Fresenius Medical Care AG & Co. (FMS), GlaxoSmithKline (GSK) and Teva Pharmaceutical Industries (TEVA). Who are BIOFRONTERA AG/ADR's key executives? BIOFRONTERA AG/ADR's management team includes the folowing people: Prof. Hermann Lübbert, Co-Founder, Chairman of Management Board & CEO (Age 63)Mr. Thomas Schaffer, CFO & Member of Management Board (Age 56)Mr. Christoph Dünwald, Chief Commercial Officer, Head of Sales & Marketing and Additional Member of Management Board (Age 51)Mr. Alexander Richardson, Head of UK Sales Team When did BIOFRONTERA AG/ADR IPO? (BFRA) raised $18 million in an IPO on Wednesday, February 14th 2018. The company issued 1,500,000 shares at $11.00-$13.00 per share. Benchmark acted as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers. How do I buy shares of BIOFRONTERA AG/ADR? Shares of BFRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is BIOFRONTERA AG/ADR's stock price today? One share of BFRA stock can currently be purchased for approximately $11.25. How big of a company is BIOFRONTERA AG/ADR? BIOFRONTERA AG/ADR has a market capitalization of $252.23 million and generates $24.93 million in revenue each year. BIOFRONTERA AG/ADR employs 149 workers across the globe.View Additional Information About BIOFRONTERA AG/ADR. What is BIOFRONTERA AG/ADR's official website? The official website for BIOFRONTERA AG/ADR is http://www.biofrontera.com/. How can I contact BIOFRONTERA AG/ADR? BIOFRONTERA AG/ADR's mailing address is HEMMELRATHER WEG 201, LEVERKUSEN 2M, D-51377. The company can be reached via phone at 011-49-2148-7600 or via email at [email protected] MarketBeat Community Rating for BIOFRONTERA AG/ADR (NASDAQ BFRA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 125 (Vote Outperform)Underperform Votes: 130 (Vote Underperform)Total Votes: 255MarketBeat's community ratings are surveys of what our community members think about BIOFRONTERA AG/ADR and other stocks. Vote "Outperform" if you believe BFRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BFRA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: How is the LIBOR rate calculated?
